AGP

Dược phẩm Agimexpharm ·UPCOM ·2026Q1

▼ Slightly negative

Capital efficiency remains weak ROE 4.90%, −0.87pp YoY
Price
35,900
Latest close
02 Jun 2026
P/E 17.47x
P/B 1.94x
EPS 2,055
BVPS 18,476
ROE 10.9%
ROA 4.2%
Profit Margin 6.2%
Asset Turnover 0.68x
Equity Mult. 2.60x

TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity

What Is Changing

On a TTM 2026Q1 basis, AGP is maintaining revenue, but margins are compressing slightly — profit is at an all-time high. What remains unclear is whether this is a short-term fluctuation or costs are starting to outpace revenue.

TTM REVENUE
VND 851bn
+4.7%YoY
NET MARGIN
6.19%
−0.2ppYoY
TTM NET PROFIT
VND 53bn
+1.2%YoY
Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24 Q4'23 Q3'23 Q2'23
Revenue 207.9 233.2 203.6 206.6 201.3 223.5 198.7 189.6 181.4 203.9 175.8 175.4
Growth -11% +15% -1% +3% -10% +12% +5% +5% -11% +16% +0%
Net Income 13.5 14.6 12.8 11.7 13.1 14.4 12.6 11.9 10.0 9.9 10.7 10.0
Net Margin 6.49% 6.28% 6.30% 5.67% 6.50% 6.46% 6.32% 6.30% 5.49% 4.85% 6.09% 5.72%

Drivers of AGP's profit

TTM

Net profit attributable to parent increased vs last year, mainly helped by higher gross profit. Supporting and offsetting drivers:

Gross profit ↑ 19.8bn
Finance costs ↑ 9.3bn
Selling expenses ↑ 2.8bn
Financial income ↓ 2.1bn
Other profit ↓ 2.1bn
TTM

Net profit attributable to parent increased vs prior quarter, mainly helped by higher gross profit. Supporting and offsetting drivers:

Gross profit ↑ 4.7bn
Financial income ↑ 0.3bn
Other profit ↓ 2.9bn
Finance costs ↑ 1.0bn
Selling expenses ↑ 0.6bn
Administrative expenses ↑ 0.1bn

Financial Highlights

Detailed analysis of each financial dimension

ROE = Profit Margin × Asset Turnover × Equity Multiplier

2025Q1 14.2% = 6.4% × 0.78 × 2.85
2026Q1 10.9% = 6.2% × 0.68 × 2.60

ROE fell from 14.2% to 10.9% — all three components weakened, with leverage being the main drag.

Net margin: 6.2% -0.2pp Asset turnover: 0.68x -0.10x Leverage: 2.60x -0.25x

Is the profit sustainable?

Margins narrowed but earnings quality remains clean — pressure is mainly operational.

very positive positive stable watch under pressure

What is driving the margin?

Net margin stands at 6.19%, broadly flat versus the same period. Supportive factors and pressure points are offsetting one another.

Margin is nearly flat but the underlying components are moving — this is a transitional phase, more time is needed to see the real trend.

Profitability trend

Net Margin 6.19% −0.2pp
Gross Margin 30.57% +1.0pp
SG&A / Revenue 17.84% −0.3pp

TTM YoY · 2025Q1 -> 2026Q1

Is capital being used efficiently?

Evaluate capital, asset, and working-capital efficiency.

Is capital being deployed efficiently?

ROIC narrowed to 4.90%, falling 0.9pp. That translates to 4.90 in after-tax operating profit for every 100 units of operating capital. The main pressure came from capital turnover fell 0.14x — capital is being absorbed faster than revenue is being generated; while invested capital expanded strongly by 200bn.

Pressure came from turnover — added capital has not been absorbed quickly enough, a typical investment-cycle dynamic.

Watchpoints

ROIC remains low

ROIC is currently 4.90% — below the typical cost-of-capital threshold; worth tracking whether upcoming periods can rise above this level.

CAPITAL EFFICIENCY TREND

TTM YoY · 2025Q1 -> 2026Q1

ROIC 4.90% −0.9pp
NOPAT Margin 6.11% +0.0pp
Capital Turnover 0.80x −0.14x
Average Invested Capital 1,062.3bn +200.1bn

Balance Sheet

Leverage is elevated, requiring monitoring — liabilities at 2.00x equity, net debt at 1.08x equity.

Inventory ended the period at 341.5bn, roughly 25.0% of total assets.

Over the last 12 months, working capital absorbed 66.8bn of cash, mainly because of higher receivables and higher inventories.

Working Capital Drivers

TTM YoY · 2025Q1 -> 2026Q1

Receivables increased → lower CFO: −54.2bn
Inventories increased → lower CFO: −8.5bn
Payables decreased → lower CFO: −4.1bn

Working Capital Efficiency

Cash conversion cycle lengthened by 1.5 days versus the same period last year. The main moves came from DIO rose 8.2 days, DSO fell 5.7 days, and DPO rose 1.1 days.

Working capital cycle is flat — components are offsetting each other.

Watchpoints

Cash conversion cycle remains stretched

CCC stands at 204.8 days, suggesting that working capital remains tied up for a relatively long operating cycle.

Inventory turnover is slowing

DIO increased by +8.2 days, suggesting more capital is being tied up in inventories.

Working Capital Efficiency

TTM YoY · 2025Q1 -> 2026Q1

Receivables 75.4 days −5.7 days
Inventory 203.4 days +8.2 days
Payables 74.0 days +1.1 days
Cash Conversion Cycle 204.8 days +1.5 days

Is financial risk significant?

Leverage is safe but FCF is negative at 93.7bn due to capex of 88.1bn — an investment choice, not an urgent risk.

Leverage & Liquidity

Leverage warrants monitoring, with net debt / equity at 1.08x and interest coverage only at 1.51x.

At present, short-term debt accounts for 73.7% of total debt, cash equals 6.0% of debt, and total debt stands at 649.2bn.

Watchpoints

Net leverage is elevated

Net debt / equity stands at 1.08x, increasing balance-sheet pressure.

Interest coverage is thin

Interest coverage is 1.51x, leaving limited room to absorb financing costs.

Leverage and liquidity trend

Net Debt / Equity 1.08x −0.31x
Interest Coverage 1.51x −0.29x
Cash / Debt 6.0% +2.1pp
Short-term Debt / Total Debt 73.7% −4.7pp
CFO / NI -0.11x −1.56x

TTM YoY · 2025Q1 -> 2026Q1

Cash Flow

With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 138.5bn in 2025, against investing cash flow of -34.1bn.

Post-investment cash flow was positive +104.4bn. Financing cash flow was positive +53.1bn.

CFO / net income was -0.11x.

After spending +88.1bn on fixed-asset investment, the business generated trailing free cash flow of −93.7bn.

Cash Conversion

TTM Cash Conversion · 2025Q1 -> 2026Q1

CFO TTM 5.6bn −81.2bn
Cash Capex 88.1bn −129.7bn
FCF TTM −93.7bn +48.4bn

Investment Takeaway

The business is under real pressure, but the current picture has not turned broadly adverse. A notable area has clearly weakened, making the near-term outlook hard to call bright; even so, other parts of the business are still holding up, with capital efficiency remains weak remaining the main constraint, with ROIC at 4.9%. The main offsetting support comes from earnings conversion is confirmed, with CFO/NI at -0.11x.

Improvement: earnings conversion looks more confirmed, with CFO / net income at -0.11x.

Key risk: Capital efficiency remains weak.

Statement Data

Item 2025 2024 2023 2022 2021
Net Revenue
844.7 793.3 725.1 687.0 521.8
Cost of Goods Sold
589.1 560.2 510.4 457.7 0.0
Gross Profit
255.5 233.0 214.7 229.4 186.3
Financial Expenses
42.6 32.6 39.1 28.6 -21.3
Selling Expenses
103.4 97.7 82.6 108.2 -95.1
General and Administrative Expenses
48.1 45.1 39.7 40.7 -29.8
Operating Profit
62.2 60.6 53.9 52.9 40.8
Profit Before Tax
65.9 60.5 54.2 53.2 41.1
Net Income
52.0 48.9 43.6 42.9 33.1
Profit Attributable to Parent
52.0 48.9 43.6 42.9 33.1
Earnings per Share
1,810.00 1,940.00 2,119.00 2,272.00 1,097.00

Explore Other Stocks In The Same Sector

DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, DHD, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP

Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.